ELVN
Enliven Therapeutics Inc.
$42.53
+$0.99(+2.38%)
51
Overall
60
Value
54
Tech
39
Quality
Market Cap
$1.12B
Volume
538.92K
52W Range
$14.79 - $48.53
Target Price
$56.78
Company Overview
| Mkt Cap | $1.12B | Price | $42.53 |
| Volume | 538.92K | Change | +2.38% |
| P/E Ratio | -10.8 | Open | $42.04 |
| Revenue | -- | Prev Close | $41.54 |
| Net Income | $-103.7M | 52W Range | $14.79 - $48.53 |
| Div Yield | N/A | Target | $56.78 |
| Overall | 51 | Value | 60 |
| Quality | 39 | Technical | 54 |
No chart data available
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Latest News
Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)
Christine Brown•10 days ago
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Molina Healthcare (MOH) and Aldeyra Therapeutics (ALDX)
Catie Powers•15 days ago
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Molina Healthcare (MOH) and Aldeyra Therapeutics (ALDX)
Catie Powers•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELVN | $42.53 | +2.4% | 538.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enliven Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW